Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasmin Abaza

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Blood|November 14, 2024
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDSYasmin Abaza, Amy E DeZern
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?Yasmin Abaza, Amir T Fathi
Cancer Journal (Sudbury, Mass.)|May 17, 2023
Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in?Yasmin Abaza, Anand Ashwin Patel
Cells|July 27, 2022
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic SyndromesYasmin Abaza, Amer M Zeidan
Current Hematologic Malignancy Reports|April 30, 2015
Selecting the best frontline treatment in chronic myeloid leukemiaMusa Yilmaz, Yasmin Abaza, Elias Jabbour
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 25, 2024
Advancements and Challenges in the Treatment of AMLYasmin Abaza, Christine McMahon, Jacqueline S Garcia
Hematology. American Society of Hematology. Education Program|December 5, 2025
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?Himachandana Atluri, Yasmin Abaza, Jessica K Altman
Blood Reviews|June 1, 2025
Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insightsAlain Mina, Yazan Madanat, Yasmin Abaza, et al.
Expert Opinion on Pharmacotherapy|August 8, 2022
Advances in the pharmacological management of acute myeloid leukemia in adultsYazan Numan, Yasmin Abaza, Jessica K Altman, et al.
International Journal of Hematology|November 11, 2016
Primary autoimmune myelofibrosis: a case report and review of the literatureYasmin Abaza, C Cameron Yin, Carlos E Bueso-Ramos, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Blood|November 14, 2024
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDSYasmin Abaza, Amy E DeZern
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?Yasmin Abaza, Amir T Fathi
Cancer Journal (Sudbury, Mass.)|May 17, 2023
Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in?Yasmin Abaza, Anand Ashwin Patel
Cells|July 27, 2022
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic SyndromesYasmin Abaza, Amer M Zeidan
Current Hematologic Malignancy Reports|April 30, 2015
Selecting the best frontline treatment in chronic myeloid leukemiaMusa Yilmaz, Yasmin Abaza, Elias Jabbour
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 25, 2024
Advancements and Challenges in the Treatment of AMLYasmin Abaza, Christine McMahon, Jacqueline S Garcia
Hematology. American Society of Hematology. Education Program|December 5, 2025
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?Himachandana Atluri, Yasmin Abaza, Jessica K Altman
Blood Reviews|June 1, 2025
Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insightsAlain Mina, Yazan Madanat, Yasmin Abaza, et al.
Expert Opinion on Pharmacotherapy|August 8, 2022
Advances in the pharmacological management of acute myeloid leukemia in adultsYazan Numan, Yasmin Abaza, Jessica K Altman, et al.
International Journal of Hematology|November 11, 2016
Primary autoimmune myelofibrosis: a case report and review of the literatureYasmin Abaza, C Cameron Yin, Carlos E Bueso-Ramos, et al.
Pageof 5